SCHEMBL2331497

SCHEMBL2331497

CC(C)(C)N(C([O])=O)C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19473677 0.74 ALDH1A1 (0.33) ALDH1A1TSHR
SCHEMBL497097 0.71 TSHR (0.39) ALDH1A1TSHR
SCHEMBL74603 0.71 LMNA (0.33) ALDH1A1TSHR
SCHEMBL4722121 0.69 TSHR (0.30) TSHR
SCHEMBL42771 0.69 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL3063397 0.69 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL498108 0.69 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL42772 0.69 LMNA (0.35) ALDH1A1TSHR
SCHEMBL8101247 0.69 MEN1 (0.33) ALDH1A1TSHR
SCHEMBL966652 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2018-01-18 US disclosed
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO, INC. 2016-09-22 US disclosed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 EP disclosed
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 EP disclosed
WO-2014144801-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC. (US) 2014-09-18 WO disclosed
EP-2533645-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2012-12-19 EP disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
WO-2011100373-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-08-18 WO disclosed
US-20090137629-A1 Sigma receptor binding agent containing indanone derivative IIMURA YOICHI 2009-05-28 US disclosed
US-5523407-A ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS, FOR TREATING OR PREVENTING HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-06-04 US disclosed
US-5362742-A Acyl CoA: cholesterol acyltransferase TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-08 US disclosed
US-5318969-A Hypotensive, vasodilating action and muscle relaxants YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-06-07 US disclosed
EP-0505565-B1 QUINOLINE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-04-27 EP disclosed
EP-0339562-B1 BENZOPYRAN COMPOUND AND ITS PHARMACEUTICAL USE YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1993-09-15 EP disclosed
EP-0505565-A1 QUINOLINE DERIVATIVES, THEIR PRODUCTION AND USE. TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1992-09-30 EP disclosed
US-5143936-A Benzopyran compound and its pharmaceutical use YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1992-09-01 US disclosed
WO-1991009017-A1 QUINOLINE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-06-27 WO disclosed
US-5021432-A Hypotensive agents YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1991-06-04 US disclosed
EP-0339562-A1 Benzopyran compound and its pharmaceutical use YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1989-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, BACE1, GRIN2A ALDH1A1 1226/4885TSHR 1591/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ALDH1A1 1226/4885TSHR 1591/4885
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885TSHR 4373/4885
US-20090137629-A1 Sigma receptor binding agent containing indanone derivative SIGMAR1, TMEM97, OPRK1 ALDH1A1 1235/4885TSHR 388/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885TSHR 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.